Value of inflammatory biomarkers in predicting the outcome of patients with muscle-invasive bladder cancer receiving different neoadjuvant treatment regimens

Li Bo; Yang Lei; Pu Linlong; He Ruibao; Tang Zhaobing

doi:10.13406/j.cnki.cyxb.003297

您当前的位置：

首页 >

文章列表页 >

Value of inflammatory biomarkers in predicting the outcome of patients with muscle-invasive bladder cancer receiving different neoadjuvant treatment regimens

Carcinoma of bladder | 更新时间：2025-10-21

- Value of inflammatory biomarkers in predicting the outcome of patients with muscle-invasive bladder cancer receiving different neoadjuvant treatment regimens
- Journal of Chongqing Medical University Vol. 48, Issue 8, Pages: 880-884(2023)
- 作者机构：
  
  重庆医科大学附属第一医院泌尿外科，重庆 400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003297
  CLC： R737.14
- Received：19 May 2023，
  
  Revised：2023-06-18，
  
  Accepted：29 June 2023，
  
  Published：28 August 2023
- 稿件说明：
移动端阅览
李波,杨雷,蒲麟龙,等.炎症标志物对肌层浸润性膀胱癌患者接受不同新辅助治疗方案疗效预测分析[J].重庆医科大学学报,2023,48(8):880-884.

Li Bo,Yang Lei,Pu Linlong,et al.Value of inflammatory biomarkers in predicting the outcome of patients with muscle-invasive bladder cancer receiving different neoadjuvant treatment regimens[J].Journal of Chongqing Medical University,2023,48(8):880-884.
李波,杨雷,蒲麟龙,等.炎症标志物对肌层浸润性膀胱癌患者接受不同新辅助治疗方案疗效预测分析[J].重庆医科大学学报,2023,48(8):880-884. DOI： 10.13406/j.cnki.cyxb.003297.

Li Bo,Yang Lei,Pu Linlong,et al.Value of inflammatory biomarkers in predicting the outcome of patients with muscle-invasive bladder cancer receiving different neoadjuvant treatment regimens[J].Journal of Chongqing Medical University,2023,48(8):880-884. DOI： 10.13406/j.cnki.cyxb.003297.

摘要

目的

探讨炎症标志物对肌层浸润性膀胱癌患者接受新辅助治疗效果的预测价值。

方法

回顾性分析2020年1月至2023年2月于重庆医科大学附属第一医院泌尿外科就诊并接受新辅助治疗的肌层浸润性膀胱癌患者临床资料，分析中性粒细胞与淋巴细胞比值（neutrophil-to-lymphocyte ratio，NLR）、衍生中性粒细胞与淋巴细胞比值（derived neutrophil-lymphocyte ratio，dNLR）和全身免疫炎症指数（systemic immune-inflammation index，SII）等炎症标志物对新辅助治疗效果的影响，应用受试者工作特征（receiver operating characteristic，ROC）曲线确定最佳截断值，从而将患者分为高、低亚组，通过对比分析各亚组间患者相关临床、病理参数及新辅助治疗效果差异。进一步比较炎症指标的高、低对患者接受新辅助治疗效果的影响。

结果

临床、病理参数在炎症指标高、低亚组间差异无统计学意义（

0.05）。而在炎症指标高、低亚组中，患者接受新辅助治疗的客观缓解率（objective response rate，ORR）、疾病控制率（disease control rate，DCR）差异有统计学意义（

0.05），并且更高的炎症指标与更差的疗效相关。此外，4种新辅助治疗方案间，患者的ORR、DCR差异无统计学意义（

0.05）。

结论

新辅助治疗前外周血炎症指标NLR、dNLR和SII可以作为判断新辅助疗效的潜在指标。

Abstract

Objective

To investigate the value of inflammatory biomarkers in predicting the efficacy of neoadjuvant therapy in patients with muscle-invasive bladder cancer.

Methods

A retrospective analysis was performed for the clinical data of patients with muscle-invasive bladder cancer who attended Department of Urology，The First Affiliated Hospital of Chongqing Medical University，from January 2020 to February 2023 and received neoadjuvant therapy. The influence of related inflammatory biomarkers on the efficacy of neoadjuvant therapy was analyzed，including neutrophil-to-lymphocyte ratio（NLR），derived neutrophil-to-lymphocyte ratio（dNLR），and systemic immune-inflammation index（SII），and the receiver operating characteristic（ROC） curve was used to determine the optimal cut-off values. Then the patients were divided into high and low inflammatory biomarker subgroups to investigate the differences in clinicopathological parameters and the efficacy of neoadjuvant therapy. Finally，a comparative analysis was performed to investigate the influence of inflammatory biomarkers on the outcome of patients receiving neoadjuvant therapy.

Results

There were no significant differences in clinicopathological parameters between the high and low inflammatory biomarker subgroups（

0.05）. There were significant differences in objective response rate（ORR） and disease control rate（DCR） after neoadjuvant therapy between the high and low inflammatory biomarker subgroups（

0.05），and higher levels of inflammatory biomarker were associated with a less favorable therapeutic outcome. In addition，there were no significant differences in ORR and DCR between the four neoadjuvant treatment regi

mens（

0.05）.

Conclusion

The peripheral blood inflammatory biomarkers NLR，dNLR，and SII before neoadjuvant therapy can be used as potential indicators to judge the efficacy of neoadjuvant therapy.

关键词

Keywords

references

Sung H ， Ferlay J ， Siegel RL ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

Hermans TJN ， Voskuilen CS ， van der Heijden MS ， et al . Neoadjuvant treatment for muscle-invasive bladder cancer：the past，the present，and the future [J ] . Urol Oncol ， 2018 ， 36 （ 9 ）： 413 - 422 .

Spiess PE ， Agarwal N ， Bangs R ， et al . Bladder cancer，version 5.2017，NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw ， 2017 ， 15 （ 10 ）： 1240 - 1267 .

Ma CQ ， Lu BX ， Diao CW ， et al . Preoperative neutrophil-lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer [J ] . Onco Targets Ther ， 2016 ， 9 ： 4917 - 4922 .

Diakos CI ， Charles KA ， McMillan DC ， et al . Cancer-related inflammation and treatment effectiveness [J ] . Lancet Oncol ， 2014 ， 15 （ 11 ）： e493 - e503 .

Tong YS ， Tan J ， Zhou XL ， et al . Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage Ⅲ non-small cell lung cancer [J ] . J Transl Med ， 2017 ， 15 （ 1 ）： 221 .

Prajapati HJ ， Spivey JR ， Hanish SI ， et al . mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma（HCC）treated by doxorubicin drug-eluting beads transarterial chemoembolization（DEB TACE） [J ] . Ann Oncol ， 2013 ， 24 （ 4 ）： 965 - 973 .

Necchi A ， Anichini A ， Raggi D ， et al . Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma（PURE-01）：an open-label，single-arm，phase Ⅱ study [J ] . J Clin Oncol ， 2018 ， 36 （ 34 ）： 3353 - 3360 .

Rose TL ， Harrison MR ， Deal AM ， et al . Phase Ⅱ study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer [J ] . J Clin Oncol ， 2021 ， 39 （ 28 ）： 3140 - 3148 .

Sheng XN ， Yan XQ ， Wang L ， et al . Open-label，multicenter，phase Ⅱ study of RC48-ADC，a HER2-targeting antibody-drug conjugate，in patients with locally advanced or metastatic urothelial carcinoma [J ] . Clin Cancer Res ， 2021 ， 27 （ 1 ）： 43 - 51 .

Zhou L ， Xu HY ， Li SM ， et al . Study RC48-C014：Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma [J ] . J Clin Oncol ， 2022 ， 40 （ Suppl 6 ）： 515 .

Liang W ， Ferrara N . The complex role of neutrophils in tumor angiogenesis and metastasis [J ] . Cancer Immunol Res ， 2016 ， 4 （ 2 ）： 83 - 91 .

Chang PH ， Wu MH ， Liu SY ， et al . The prognostic roles of pretreatment circulating tumor cells，circulating cancer stem-like cells，and programmed cell death-1 expression on peripheral lymphocytes in patients with initially unresectable，recurrent or metastatic head and neck cancer：an exploratory study of three biomarkers in one-time blood drawing [J ] . Cancers ， 2019 ， 11 （ 4 ）： 540 .

Schlesinger M . Role of platelets and platelet receptors in cancer metastasis [J ] . J Hematol Oncol ， 2018 ， 11 （ 1 ）： 125 .

Black AJ ， Zargar H ， Zargar-Shoshtari K ， et al . The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy [J ] . Urol Oncol ， 2020 ， 38 （ 1 ）： 3.e17 - 3.e27 .

Buisan O ， Orsola A ， Areal J ， et al . Low pretreatment neutrophil-to-lymphocyte ratio predicts for good outcomes in patients receiving neoadjuvant chemotherapy before radical cystectomy for muscle invasive bladder cancer [J ] . Clin Genitourin Cancer ， 2017 ， 15 （ 1 ）： 145 - 151 .

Dalpiaz O ， Pichler M ， Mannweiler S ， et al . Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma [J ] . Br J Cancer ， 2014 ， 110 （ 10 ）： 2531 - 2536 .

Li JZ ， Cao DH ， Huang Y ， et al . The prognostic and clinicopathological significance of systemic immune-inflammation index in bladder cancer [J ] . Front Immunol ， 2022 ， 13 ： 865643 .

Murthy P ， Zenati MS ， Al Abbas AI ， et al . Prognostic value of the systemic immune-inflammation index（SII） after neoadjuvant therapy for patients with resected pancreatic cancer [J ] . Ann Surg Oncol ， 2020 ， 27 （ 3 ）： 898 - 906 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of ADC combined with PD-1 inhibitors versus GC regimen in neoadjuvant therapy for bladder cancer

Research advances in liquid biopsy for bladder cancer

Construction of a model for bladder cancer prognosis and immune analysis based on m6A-related long non-coding RNAs

Current development of wireless capsule cystoscope

Value of inflammatory，pyroptosis，and ferroptosis biomarkers in the treatment and prognosis of bladder cancer

Related Author

Mei Yuhua

Li Li

Hu Xiao

Gou Xin

Zhang Bingnan

Liu Peihua

Fan Benyi

Yu Haitao

Related Institution

Department of Urology，Xiangya Hospital，Central South University/National Clinical Research Center for Geriatric Disorders

Department of Urology,Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University

Department of Urology,The Second Hospital,University of South China

Department of Urology,Pingxiang People’s Hospital

Department of Urinary Surgery，Xinxiang Central Hospital，The Fourth Clinical College of Xinxiang Medical University

⁰